ArticleDisease markers2022

Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study.

Li-Hua Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.